144 related articles for article (PubMed ID: 12360109)
21. Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity.
Kiiski JI; Neuvonen M; Kurkela M; Hirvensalo P; Hämäläinen K; Tarkiainen EK; Sistonen J; Korhonen M; Khan S; Orpana A; Filppula AM; Lehtonen M; Niemi M
Hum Genomics; 2024 Feb; 18(1):11. PubMed ID: 38303026
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation.
Li D; Pain O; Fabbri C; Wong WLE; Lo CWH; Ripke S; Cattaneo A; Souery D; Dernovsek MZ; Henigsberg N; Hauser J; Lewis G; Mors O; Perroud N; Rietschel M; Uher R; Maier W; Baune BT; Biernacka JM; Bondolfi G; Domschke K; Kato M; Liu YL; Serretti A; Tsai SJ; Weinshilboum R; ; ; McIntosh AM; Lewis CM
medRxiv; 2023 Dec; ():. PubMed ID: 37425775
[TBL] [Abstract][Full Text] [Related]
23. Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes.
Yang Y; Zhang X; Wang Y; Xi H; Xu M; Zheng L
Front Pharmacol; 2024; 15():1342515. PubMed ID: 38756374
[TBL] [Abstract][Full Text] [Related]
24. A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis.
Kim Y; Rhee SJ; Park WB; Yu KS; Jang IJ; Lee S
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30744151
[TBL] [Abstract][Full Text] [Related]
25. Genetic Variation in
Soria-Chacartegui P; Zubiaur P; Ochoa D; Villapalos-García G; Román M; Matas M; Figueiredo-Tor L; Mejía-Abril G; Calleja S; de Miguel A; Navares-Gómez M; Martín-Vilchez S; Abad-Santos F
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839726
[TBL] [Abstract][Full Text] [Related]
26. A Semi-Mechanistic Population Pharmacokinetic Model of Noscapine in Healthy Subjects Considering Hepatic First-Pass Extraction and CYP2C9 Genotypes.
Chen Z; Taubert M; Chen C; Boland J; Dong Q; Bilal M; Dokos C; Wachall B; Wargenau M; Scheidel B; Wiesen MHJ; Schaeffeler E; Tremmel R; Schwab M; Fuhr U
Drugs R D; 2024 May; ():. PubMed ID: 38809387
[TBL] [Abstract][Full Text] [Related]
27. Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient population.
Dagenais S; Lee C; Cronenberger C; Wang E; Sahasrabudhe V
Clin Transl Sci; 2024 Mar; 17(3):e13741. PubMed ID: 38445532
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Marathe DD; Jauslin PM; Kleijn HJ; de Miranda Silva C; Chain A; Bateman T; Shaw PM; Abraham AK; Kauh EA; Liu Y; Perini RF; de Alwis DP; Jain L
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1499-1510. PubMed ID: 37596839
[TBL] [Abstract][Full Text] [Related]
29. Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth.
Wisner KL; Avram MJ; George AL; Abramova TV; Yang A; Caritis SN; Costantine MM; Stika CS
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):100-106. PubMed ID: 38421920
[TBL] [Abstract][Full Text] [Related]
30. An increase in urinary primaquine and a reduction in urinary primaquine-5,6-orthoquinone in the Thai population with CYP2D6 reduced enzyme function.
Pookmanee W; Thongthip S; Mungthin M; Sukasem C; Tankanitlert J; Chariyavilaskul P; Wittayalertpanya S
Heliyon; 2024 Jan; 10(2):e24351. PubMed ID: 38293439
[TBL] [Abstract][Full Text] [Related]
31. Phenotype-Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism.
Böhm R; Bruckmueller H; Oswald S; Hübenthal M; Kaehler M; Ehmke L; Höcker J; Siegmund W; Franke A; Cascorbi I
Clin Pharmacol Ther; 2024 Jul; 116(1):204-216. PubMed ID: 38637968
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic Variants Associated with Fluoxetine Pharmacokinetics from a Bioequivalence Study in Healthy Subjects.
Díaz-Tufinio CA; Palma-Aguirre JA; Gonzalez-Covarrubias V
J Pers Med; 2023 Sep; 13(9):. PubMed ID: 37763120
[TBL] [Abstract][Full Text] [Related]
33. Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths.
Aly SM; Hennart B; Gaulier JM; Allorge D
Toxics; 2024 Mar; 12(4):. PubMed ID: 38668482
[TBL] [Abstract][Full Text] [Related]
34. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.
de Vos A; van der Weide J; Loovers HM
Pharmacogenomics J; 2011 Oct; 11(5):359-67. PubMed ID: 20531370
[TBL] [Abstract][Full Text] [Related]
35. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets.
Kirchheiner J; Henckel HB; Franke L; Meineke I; Tzvetkov M; Uebelhack R; Roots I; Brockmöller J
Pharmacogenet Genomics; 2005 Aug; 15(8):579-87. PubMed ID: 16007002
[TBL] [Abstract][Full Text] [Related]
36. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
[TBL] [Abstract][Full Text] [Related]
37. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks JK; Swen JJ; Thorn CF; Sangkuhl K; Kharasch ED; Ellingrod VL; Skaar TC; Müller DJ; Gaedigk A; Stingl JC;
Clin Pharmacol Ther; 2013 May; 93(5):402-8. PubMed ID: 23486447
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics: from bench to byte--an update of guidelines.
Swen JJ; Nijenhuis M; de Boer A; Grandia L; Maitland-van der Zee AH; Mulder H; Rongen GA; van Schaik RH; Schalekamp T; Touw DJ; van der Weide J; Wilffert B; Deneer VH; Guchelaar HJ
Clin Pharmacol Ther; 2011 May; 89(5):662-73. PubMed ID: 21412232
[TBL] [Abstract][Full Text] [Related]
39. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
